ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1611

Putative Role of the Histidine and Tryptophan Biochemical Pathways in the Mode of Action of Upadacitinib in Patients with Ankylosing Spondylitis

Thierry Sornasse1, Liang Li2, Shuang Zhao2, Xiaohang Wang2, Fang Cai3, Yingtao Bi4, In-Ho Song5, Stephanie Wichuk6, Robert G. Lambert7 and Walter P Maksymowych8, 1AbbVie, South San Francisco, CA, 2The Metabolomics Innovation Centre and Department of Chemistry, University of Alberta, Edmonton, AB, Canada, 3AbbVie, Redwood City, CA, 4AbbVie, Inc, Worcester, MA, 5AbbVie, Inc., North Chicago, IL, 6University of Alberta, Edmonton, AB, Canada, 7Department of Medicine, Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 8Department of Medicine, University of Alberta, Edmonton, AB, Canada

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), Biomarkers, metabolomics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes I: Diagnosis and Disease Activity

Session Type: Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Upadacitinib (UPA) 15 mg QD is efficacious in patients with active ankylosing spondylitis (AS) exhibiting inadequate responses to nonsteroidal anti-inflammatory drugs (NSAIDs-IR).1 We determined the impact of UPA on the global metabolome in these patients.

Methods: Baseline (BL), weeks 4, and 14 serum samples were obtained from a subset of patients enrolled in SELECT-AXIS1 (PBO, n = 59 out of 94; UPA, n = 59 out of 93). Patients met the modified New York AS criteria and had active disease at BL. Samples were processed using dansyl-12C-labeling kits or DmPA-12C-labeling kits for each chemical-group channel and analyzed by LC-MS–based metabolomics. Data analysis was performed using IsoMS Pro 1.2.15 (NovaMT Inc.) and metabolite identification was done using NovaMT Metabolite Database v2.0.2 Tier 1 and 2 metabolites matched single compounds from a labeled metabolite library and a linked identity library, respectively. Tier 3 metabolites matched more than 1 compound. Differentially modulated metabolites (DMM) were identified using a mixed linear model measuring change from BL for each treatment group (selection criteria, absolute Log10 fold change ≥ 0.079, and false discovery rate ≤ 0.1). Pathway enrichment analyses were conducted using MetaboAnalyst 5.0.3 Relationships between metabolite level changes, and clinical changes were assessed by Pearson’s correlation.

Results: We detected a total of 8020 distinct metabolites (ie, ≥ 80% detectability across timepoints within each treatment group) across the global metabolome. From these 8020 metabolites, we identified 289 and 221 DMM at weeks 4 and 14 in the UPA group vs 32 and 89 in the PBO group, respectively (Fig. 1). Most DMM in the UPA group (187 and 144 at weeks 4 and 14, respectively) belonged to the Tier 3 identification category, and 51 and 40 at weeks 4 and 14, respectively, belonged to the Tier 1 and 2 categories. Pathway enrichment suggests UPA affects the histidine and tryptophan biochemical pathways (Fig. 2), consistent with increases in metabolites observed in the UPA group. Increases in histidine and tryptophan levels were significantly associated with an improvement in CRP levels and Ankylosing Spondylitis Disease Activity Score-CRP scores (P ≤ .05). Increases in histidine levels were also associated with the improvement in MRI Spondyloarthritis Research Consortium of Canada Spine indices.

Conclusion: This is the first comprehensive metabolome analysis of serum samples collected from patients with AS treated with UPA. Data highlight the promise of advanced metabolomics to elucidate therapeutic agent’s mode of action in AS. The putative effect of UPA on the tryptophan biochemical pathway is of particular interest because the tryptophan/kynurenine pathway is associated with chronic pain4 and is perturbed toward the degradation of tryptophan in patients with AS.5 We hypothesize that the increase in tryptophan and histidine may be related to the mode of action of UPA in NSAID-IR patients with AS.

References
1. van der Heijde D, et al. Lancet. 2019;394:2108
2. Blackmore D, et al. Metabolomics. 2020;16:10
3. Pang Z, et al. Nucleic Acids Res. 2021;49:W388
4. Jovanovic F, et al. Int J Mol Sci. 2020;21:6045
5. Eryavuz Onmaz D, et al. Int Immunopharmacol. 2021;99:108018

Supporting image 1

Supporting image 2


Disclosures: T. Sornasse, AbbVie; L. Li, Nova Medical Testing Inc. (NovaMT), Meliomics Inc., NovaMT, Bruker; S. Zhao, None; X. Wang, None; F. Cai, AbbVie; Y. Bi, AbbVie; I. Song, AbbVie; S. Wichuk, None; R. Lambert, None; W. Maksymowych, AbbVie, Boehringer-Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB, CARE Arthritis Limited.

To cite this abstract in AMA style:

Sornasse T, Li L, Zhao S, Wang X, Cai F, Bi Y, Song I, Wichuk S, Lambert R, Maksymowych W. Putative Role of the Histidine and Tryptophan Biochemical Pathways in the Mode of Action of Upadacitinib in Patients with Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/putative-role-of-the-histidine-and-tryptophan-biochemical-pathways-in-the-mode-of-action-of-upadacitinib-in-patients-with-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/putative-role-of-the-histidine-and-tryptophan-biochemical-pathways-in-the-mode-of-action-of-upadacitinib-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology